JP2017516777A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516777A5 JP2017516777A5 JP2016568934A JP2016568934A JP2017516777A5 JP 2017516777 A5 JP2017516777 A5 JP 2017516777A5 JP 2016568934 A JP2016568934 A JP 2016568934A JP 2016568934 A JP2016568934 A JP 2016568934A JP 2017516777 A5 JP2017516777 A5 JP 2017516777A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- infection
- oxazino
- oxazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004246P | 2014-05-29 | 2014-05-29 | |
| US62/004,246 | 2014-05-29 | ||
| PCT/IB2015/001585 WO2015181637A1 (en) | 2014-05-29 | 2015-05-27 | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2017516777A JP2017516777A (ja) | 2017-06-22 |
| JP2017516777A5 true JP2017516777A5 (enExample) | 2018-06-07 |
| JP6502387B2 JP6502387B2 (ja) | 2019-04-17 |
| JP6502387B6 JP6502387B6 (ja) | 2019-05-29 |
Family
ID=54329851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568934A Expired - Fee Related JP6502387B6 (ja) | 2014-05-29 | 2015-05-27 | 細菌感染の治療のための融合スピロ環ヘテロ芳香族化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10238661B2 (enExample) |
| EP (1) | EP3148546A1 (enExample) |
| JP (1) | JP6502387B6 (enExample) |
| KR (1) | KR20170007818A (enExample) |
| CN (1) | CN106659725A (enExample) |
| AU (1) | AU2015265620B2 (enExample) |
| CA (1) | CA2948438A1 (enExample) |
| EA (1) | EA033459B1 (enExample) |
| IL (1) | IL248838B (enExample) |
| MX (1) | MX365261B (enExample) |
| PH (1) | PH12016502271A1 (enExample) |
| SG (2) | SG10201906842WA (enExample) |
| TW (1) | TWI657818B (enExample) |
| WO (1) | WO2015181637A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109111465B (zh) * | 2017-06-22 | 2021-01-12 | 中国科学院上海药物研究所 | 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途 |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| SG11202101255UA (en) | 2018-08-09 | 2021-03-30 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7208490B2 (en) * | 2002-10-07 | 2007-04-24 | Pharmacia & Upjohn Company Llc | Tricyclic tetrahydroquinoline antibacterial agents |
| ATE423122T1 (de) | 2003-08-15 | 2009-03-15 | Astrazeneca Ab | Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri) |
| WO2006120563A2 (en) | 2005-05-09 | 2006-11-16 | Warner-Lambert Company Llc | Antibacterial agents |
| DOP2006000268A (es) | 2005-12-22 | 2007-07-31 | Pfizer Prod Inc | Agentes antibacterianos |
| CL2007003332A1 (es) | 2006-11-24 | 2008-06-20 | Actelion Pharmaceuticals Ltd | Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas. |
| CN101784553A (zh) | 2007-07-02 | 2010-07-21 | 阿斯利康(瑞典)有限公司 | 3-螺嘧啶三酮-喹啉衍生物及其作为抗菌药物的应用 |
| UY32174A (es) * | 2008-10-14 | 2010-05-31 | Astrazeneca Ab | Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones |
| US9040528B2 (en) | 2008-10-14 | 2015-05-26 | Astrazeneca Ab | Chemical compounds 542 |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US8952149B2 (en) | 2012-09-26 | 2015-02-10 | Zoetis Llc | Tricyclic tetrahydroquinoline antibacterial agents |
| US8889671B2 (en) | 2013-01-23 | 2014-11-18 | Astrazeneca Ab | Compounds and methods for treating bacterial infections |
-
2015
- 2015-05-27 EA EA201692250A patent/EA033459B1/ru not_active IP Right Cessation
- 2015-05-27 CA CA2948438A patent/CA2948438A1/en not_active Abandoned
- 2015-05-27 SG SG10201906842WA patent/SG10201906842WA/en unknown
- 2015-05-27 US US15/314,660 patent/US10238661B2/en not_active Expired - Fee Related
- 2015-05-27 JP JP2016568934A patent/JP6502387B6/ja not_active Expired - Fee Related
- 2015-05-27 EP EP15781402.1A patent/EP3148546A1/en not_active Withdrawn
- 2015-05-27 KR KR1020167035906A patent/KR20170007818A/ko not_active Ceased
- 2015-05-27 SG SG11201609404SA patent/SG11201609404SA/en unknown
- 2015-05-27 MX MX2016015632A patent/MX365261B/es active IP Right Grant
- 2015-05-27 WO PCT/IB2015/001585 patent/WO2015181637A1/en not_active Ceased
- 2015-05-27 CN CN201580027395.7A patent/CN106659725A/zh active Pending
- 2015-05-27 AU AU2015265620A patent/AU2015265620B2/en not_active Ceased
- 2015-05-28 TW TW104117219A patent/TWI657818B/zh not_active IP Right Cessation
-
2016
- 2016-11-08 IL IL248838A patent/IL248838B/en not_active IP Right Cessation
- 2016-11-15 PH PH12016502271A patent/PH12016502271A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Álvarez-Paino et al. | Effect of glycounits on the antimicrobial properties and toxicity behavior of polymers based on quaternized DMAEMA | |
| JP2010174030A5 (enExample) | ||
| EP3584308A3 (en) | Compositions and methods | |
| WO2016070151A8 (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
| WO2012083017A3 (en) | Controlled release oral dosage forms of poorly soluble drugs and uses thereof | |
| EP4596041A3 (en) | Farnesoid x receptor agonists and uses thereof | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| EP2911695C0 (en) | COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE BY SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC TYPES OF NEURONS | |
| WO2013169704A3 (en) | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | |
| EP4344742A3 (en) | Valbenazine salts and polymorphs thereof | |
| WO2015095241A3 (en) | Bacterial compositions and methods of use thereof for treatment of immune system disorders | |
| EP2440210A4 (en) | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES | |
| WO2014180889A8 (en) | Methods and compositions for the treatment of cancer | |
| EP2528603A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN AND OTHER DISPLAYS | |
| FR2937972B1 (fr) | Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
| EP4242240A3 (en) | Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments | |
| BRPI1010948A2 (pt) | Composição compreendendo pelo menos trans- cinamaldeído e a respectiva utilização no tratamento das infecções bacterianas, mais particularmente no tratamento das doenças nosocomiais. | |
| HK1205939A1 (en) | Parenteral formulations for administering macrolide antibiotics | |
| EP2796142A4 (en) | PHARMACEUTICAL COMPOSITION WITH DEATH CELLS FROM LACTOBACILLUS ACIDOPHILUS LB STRAIN FOR THE TREATMENT OR PREVENTION OF ALLERGIES | |
| JP2018500387A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2017519730A5 (enExample) | ||
| EP4613333A3 (en) | Pharmaceutical compositions comprising akt protein kinase inhibitors | |
| WO2017117070A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof |